Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications".

Autor: Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia., Wladysiuk M; Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland.; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland., McTaggart S; Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK., Kurdi A; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq., Allocati E; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Jakovljevic M; Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia.; Institute of Comparative Economic Studies, Hosei University Tokyo, Japan.; Department of Global Health Economics and Policy, University of Kragujevac, Serbia., Kalemeera F; Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia., Hoxha I; Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania., Nachtnebel A; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria., Sauermann R; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria., Hinteregger M; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria., Marković-Peković V; Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina., Tubic B; Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.; Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina., Petrova G; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria., Tachkov K; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria., Slabý J; State Institute for Drug Control, Prague, Czech Republic., Nejezchlebova R; State Institute for Drug Control, Prague, Czech Republic., Krulichová IS; Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic., Laius O; State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia., Selke G; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany., Langner I; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany., Harsanyi A; Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary., Inotai A; Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary., Jakupi A; Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo., Henkuzens S; Independent Consultant, Riga, Latvia., Garuolienė K; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Gulbinovič J; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Bonanno PV; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Department of Health Services Management, University of Malta, Valletta, Malta., Rutkowski J; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland., Ingeberg S; Medicines Committee, Oslo University Hospitals, Oslo, Norway., Melien Ø; Medicines Committee, Oslo University Hospitals, Oslo, Norway., Mardare I; Faculty of Medicine, Public Health and Management Department, 'Carol Davila' University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania., Fürst J; Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia., MacBride-Stewart S; Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK., Holmes C; NHS Lothian, Edinburgh, UK., Pontes C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain., Zara C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain., Pedrola MT; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain., Hoffmann M; NEPI-Nätverk för Läkemedelsepidemiologi, Stockholm, Sweden., Kourafalos V; National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece., Pisana A; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden., Banzi R; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Campbell S; Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.; NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK., Wettermark B; Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden.

Publikováno v: BioMed research international [Biomed Res Int] 2023 Apr 07; Vol. 2023, pp. 9757348. Date of Electronic Publication: 2023 Apr 07 (Print Publication: 2023).

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.

Autor: Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia., Wladysiuk M; Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland.; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland., McTaggart S; Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK., Kurdi A; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq., Allocati E; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Jakovljevic M; Department of Global Health Economics and Policy, University of Kragujevac, Kragujevac, Serbia.; Institute of Comparative Economic Studies, Faculty of Economics, Hosei University Tokyo, Tokyo, Japan., Kalemeera F; Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia., Hoxha I; Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania., Nachtnebel A; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria., Sauermann R; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria., Hinteregger M; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria., Marković-Peković V; Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina., Tubic B; Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.; Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina., Petrova G; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria., Tachkov K; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria., Slabý J; State Institute for Drug Control, Prague, Czech Republic., Nejezchlebova R; State Institute for Drug Control, Prague, Czech Republic., Krulichová IS; Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic., Laius O; State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia., Selke G; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany., Langner I; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany., Harsanyi A; Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary., Inotai A; Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary., Jakupi A; Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo., Henkuzens S; Independent Consultant, Riga, Latvia., Garuolienė K; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Gulbinovič J; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Bonanno PV; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Department of Health Services Management, University of Malta, Valletta, Malta., Rutkowski J; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland., Ingeberg S; Medicines Committee, Oslo University Hospitals, Oslo, Norway., Melien Ø; Medicines Committee, Oslo University Hospitals, Oslo, Norway., Mardare I; Faculty of Medicine, Public Health and Management Department, 'Carol Davila' University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania., Fürst J; Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia., MacBride-Stewart S; Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK., Holmes C; NHS Lothian, Edinburgh, UK., Pontes C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain., Zara C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain., Pedrola MT; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain., Hoffmann M; NEPI-Nätverk för läkemedelsepidemiologi, Stockholm, Sweden., Kourafalos V; National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece., Pisana A; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden., Banzi R; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy., Campbell S; Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.; NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK., Wettermark B; Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden.

Publikováno v: BioMed research international [Biomed Res Int] 2021 Oct 11; Vol. 2021, pp. 9996193. Date of Electronic Publication: 2021 Oct 11 (Print Publication: 2021).

Utilisation of the ESMO-MCBS in practice of HTA.

Autor: Wild C; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria claudia.wild@hta.lbg.ac.at., Grössmann N; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria., Bonanno PV; Independent Pharmaceutical Consultant, Mellieha, Malta., Bucsics A; Department of Finance, University of Vienna, Austria., Furst J; Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia., Garuoliene K; Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania., Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden., Gulbinovič J; Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania., Jones J; Healthcare Improvement Scotland, Scottish Medicine Consortium, Glasgow, UK., Pomorski MK; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland., Emprechtinger R; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Nov; Vol. 27 (11), pp. 2134-2136. Date of Electronic Publication: 2016 Aug 08.